Rheumatology Advance Access published online on July 27, 2005
Rheumatology, doi:10.1093/rheumatology/kei019
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Lupus Research Unit, The Rayne Institute, London, UK; Immunology Department, St Thomas' Hospital, London, UK
* To whom correspondence should be addressed. Introduction. Lupus membranous nephropathy (LMN) presents a difficult clinical problem as no particular treatment has been proven to be effective. Studies have shown good results with mycophenolate mofetil (MMF) in proliferative lupus nephropathy (LN) (WHO class III and IV disease). Objectives. To study whether MMF treatment was effective in membranous predominant LN in patients resistant to or intolerant of other immunosuppressive agents. Patients and methods. We retrospectively studied 10 patients with systemic lupus erythematosus who had biopsy-proven predominant LMN (six Vc patients and four Va or Vb patients). Previous treatments included cyclophosphamide, azathioprine, ciclosporin and corticosteroids. The following parameters were recorded at baseline and follow-up: blood pressure, ECLAM, proteinuria, serum albumin and creatinine, routine haematology and immunology. Results. The study included eight women and two men, mean age 38.4 ± 7.1 yr (range 30-49 yr). The racial distribution was as follows: five Caucasian, and five Black patients. The mean treatment time with MMF was 18.8 ± 15.4 months (range 3-52 months). Twenty-four-hour urinary protein excretion was reduced from median 2.26 g ( range 0-7.92 g) to median 0.66 g (range 0.08-3.85 g) at follow-up (P = 0.0039). Serum albumin increased significantly after treatment from median 29.5 g/l (range 14.0-42.0 g/l) to 33.5 g/l (range 23.0-40.0 g/l) at follow-up (P = 0.04). There were no significant changes in serum creatinine (P = 0.55). Conclusion. MMF is a potentially useful immunosuppressive agent in reducing the proteinuria associated with membranous predominant LN.
Received January 27, 2005
Accepted June 3, 2005
Original Papers
Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy
2 Lupus Research Unit, The Rayne Institute, London, UK
3 Histopathology Department, St Thomas' Hospital, London, UK
4 Lupus Research Unit, The Rayne Institute, London, UK; Nephrology Department, Guy's and St Thomas' Hospitals, London, UK
5 Lupus Research Unit, The Rayne Institute, London, UK; Kings College London, London, UK
M. Y. Karim, E-mail: yousuf.karim{at}royalsurrey.nhs.uk
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Senthil Nayagam, A. Ganguli, M. Rathi, H. S. Kohli, K. L. Gupta, K. Joshi, V. Sakhuja, and V. Jha Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1926 - 1930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Zhu, N. Chen, Y. Lin, H. Ren, W. Zhang, W. Wang, X. Pan, and H. Yu Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1933 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Stassen, C. G. M. Kallenberg, and C. A. Stegeman Use of mycophenolic acid in non-transplant renal diseases Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1013 - 1019. [Full Text] [PDF]
|
|
|
|
 |
|
 M A Dooley Mycophenylate mofetil: what role in the treatment of lupus? Lupus, March 1, 2006; 15(3): 179 - 182. [Abstract] [PDF]
|
|